Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for aggressive brain tumors: targeted drug tested in recurrent glioblastoma

NCT ID NCT04559230

First seen Apr 02, 2026 · Last updated Apr 30, 2026 · Updated 4 times

Summary

This study tests a drug called sacituzumab govitecan in people whose glioblastoma (a fast-growing brain tumor) has come back after standard treatment. The drug targets a protein called Trop-2 found on tumor cells. Researchers want to see if it helps patients live longer compared to an older chemotherapy. About 32 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Taussig Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Texas Oncology Austin

    RECRUITING

    Austin, Texas, 78705, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.